GC Cell stands at the forefront of cell therapy innovation, offering a holistic approach that encompasses everything from research and development to bringing products to market. Our mission is to fast-track the innovation in cell and gene therapies, aiming to enhance the clinical outcomes of each & every patient and shape the future of healthcare. In collaboration with our affiliates, Artiva and BioCentriq, we possess a distinct competitive edge through (1) outstanding portfolio of CIK T cell and NK cell therapies, (2) a seamless integration from Development to Commercialization, demonstrated by a track record of treating over 10,000 patients with solid tumor, and (3) adherence to global standards through our high-quality CDMO and Cold Chain Supply.

• Immuncell-LC: Autologous CIK & CTL cell therapy approved in Korea for adjuvant HCC
• GCC4001(P1): Allogeneic, unmodified, ADCC enhanced NK cell for oncology/autoimmune
• GCC2003(IND cleared): Allogeneic, HER2 targeted CAR-NK cell
• GCC2004(Non-clinical): Allogeneic, CD19 targeted CAR-NK cell
• GCC2005(Phase I): Allogeneic, CD5 targeted CAR-NK cell
• GMP compliant Cell therapy CDMO (US and Korea)
• Cold chain supply in Korea with Daily access to 5,000+ hospitals with temp control